The investigate will conduct a cohort study to compare the growth and development, metabolism, lifestyle behavior, and health-related quality of life among three groups: children with transfusion-dependent β-thalassemia (TDT) who have received gene therapy, TDT children with lifelong supportive therapy and healthy children.
Male or female age of 3-14 years
TDT Children who have received gene therapy.
Subjects who are willing and able to provide written informed consent.
Gender same as the matched case
Diagnosis of compound α-thalassemia
Uncontrolled systemic fungal, bacterial, or viral infection
History of malignant solid tumors, myeloproliferative or immunodeficiency diseases
Diagnosed with mental illness